News

For Immediate Release

Chicago, IL – July 12, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Danaher Corp. DHR, Morgan Stanley MS, Pfizer Inc. PFE, Elite Pharmaceuticals, Inc. ELTP and Oil-Dri Corporation of America ODC.

Here are highlights from Thursday’s Analyst Blog:

Top Analyst Reports for Danaher, Morgan Stanley and Pfizer

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Danaher Corp., Morgan Stanley and Pfizer Inc., as well as two micro-cap stocks, Elite Pharmaceuticals, Inc. and Oil-Dri Corporation of America. These research reports have been hand-picked from roughly 70 reports published by our analyst team today.

You can see all of today's research reports here >>>

Danaher shares have underperformed the Zacks Diversified Operations industry over the past year (+1.7% vs. +8.4%). The Zacks analyst believes that Danaher is plagued by weakness in the biotechnology unit due to decreased demand in the bioprocessing business. The company's global presence also exposes it to forex woes.

Yet, business has been good in the life sciences segment and the Abcam acquisition has bolstered the company's growth. Also, through Danaher's DBS initiatives, it has been able to reduce the impact of supply-chain constraints and inflationary pressures.

(You can read the full research report on Danaher here >>>)

Morgan Stanley's shares have underperformed the Zacks Financial – Investment Bank industry over the past year (+20.6% vs. +31.8%). The Zacks analyst believes that uncertainty about the performance of the capital markets is a woe for the company and will likely hurt its Institutional Securities segment's prospects. Rising costs are also likely to hurt its profitability.

However, resurgence of its investment banking business and a solid pipeline will aid financials. The new strategic alliance with Mitsubishi UFJ will bolster the company's presence in Japan. Efforts to become less dependent on capital-markets-driven revenues, inorganic expansion and high rates will also benefit the company.

(You can read the full research report on Morgan Stanley here >>>)

Shares of Pfizer have underperformed the Zacks Large Cap Pharmaceuticals industry over the last six months (-1.2% vs. +16.6%). Per the Zacks analyst, the company's top line is declining due to a steep drop in revenues from its COVID-19 products. Concerns remain about its long-term growth drivers.

Yet, pipeline products like Vyndaqel and Prevnar, new launches like Abrysvo, Velsipity, Penbraya and newly acquired products, including those acquired from Seagen, are expected to drive the company's growth in the near future.

(You can read the full research report on Pfizer here >>>)

Elite Pharmaceuticals' shares have outperformed the Zacks Medical – Drugs industry over the past two years (+302.3% vs. -16.8%). The Zacks analyst believes that the successful commercial launch of the company's Elite label product line, efficient cost management, robust product pipeline (including methotrexate), strategic partnerships, and financial prudence position it for sustained growth.

However, high inventory, DEA quota challenges, market competition and dependency on key products pose risks.

(You can read the full research report on Elite Pharmaceuticals here >>>)

Oil-Dri's shares have outperformed the Zacks Chemical – Diversified industry over the past two years (+91.0% vs. +3.0%). The Zacks analyst believes that the acquisition of Ultra Pet Company and product launches like Cat's Pride Antibacterial Clumping Litter have benefited the company's performance.

However, ODC's heavy reliance on Walmart for a significant portion of its sales makes its revenues vulnerable to volatility. Also, sales of agricultural and animal health products have been falling.

(You can read the full research report on Oil-Dri here >>>)

Why Haven't You Looked at Zacks' Top Stocks?

Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.

Today you can access their live picks without cost or obligation.

See Stocks Free >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Free Report: 5 “Whisper” Stocks Poised to Stun Wall Street

Analysts may be seriously underestimating these stocks. When they announce earnings, they could immediately jump +10-20%.

See Stocks Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Morgan Stanley (MS) : Free Stock Analysis Report

Pfizer Inc. (PFE) : Free Stock Analysis Report

Danaher Corporation (DHR) : Free Stock Analysis Report

Elite Pharmaceuticals Inc. (ELTP): Free Stock Analysis Report

Oil-Dri Corporation Of America (ODC): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.